JOURNAL OF CLINICAL INVESTIGATION-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2023-02-25 时光若刻来自伊利诺伊

审稿速度:2.0 | 投稿命中率:5.0
经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？

123 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-10-28 ms2000000348120955

今天下午投稿，晚上状态变成under consideration by editorial board，祈祷

91 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-08-25 ms9000001895171984

这个杂志接受综述投稿吗

72 0

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-05-25 ms9000000891013724

第1天投，第2天就外审了。

87 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-05-10 ms6000001169870328

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗

122 27

展开27条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2019-10-25 147612bem32暂无昵称

求经验

244 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-05-16 cindichaw

好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了

84 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2021-10-11 千寻1076

10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新

2 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-04-03 王东海

3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？

60 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2116370, encodeId=a20a21163e0ae, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：23年1月13日投稿，1月20日送外审，到2月14日last modified了三次，现在2月24日了还没有收到意见，请问大家这有可能是什么情况？大概还要多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=440e1981110, createdName=时光若刻, createdTime=Sat Feb 25 00:19:20 CST 2023, time=2023-02-25, status=1, ipAttribution=伊利诺伊), GetPortalCommentsPageByObjectIdResponse(id=2096580, encodeId=a3f020965805e, content=今天下午投稿，晚上状态变成under consideration by editorial board，祈祷, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b368103155, createdName=ms2000000348120955, createdTime=Fri Oct 28 00:04:28 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241044, encodeId=fbde12410449f, content=这个杂志接受综述投稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49ed8253350, createdName=ms9000001895171984, createdTime=Thu Aug 25 23:16:28 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222487, encodeId=7490122248ea1, content=第1天投，第2天就外审了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb18135579, createdName=ms9000000891013724, createdTime=Wed May 25 23:35:29 CST 2022, time=2022-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218406, encodeId=591d12184068d, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：问下各位大佬，Under consideration by Editorial Board 下一步是 “external reviewers”吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=27, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72218153329, createdName=ms6000001169870328, createdTime=Tue May 10 11:22:59 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578704, encodeId=1e595e87048c, content=求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220080, encodeId=17311220080d0, content=好杂志，比较权威。之前一篇二审后居然拒了，后来花了小半年时间，发在NC上了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon May 16 19:08:31 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1059396, encodeId=2975105939655, content=10.6投稿，可以推荐3名审稿人，也可以推荐editor，1天后状态变成under consideration by editorial board，10.11送外审，期待有个好结果，持续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0f9e1689535, createdName=千寻1076, createdTime=Mon Oct 11 11:09:34 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208339, encodeId=a45e1208339e1, content=3.30提交，4.2送外审，目前在等待中，有没有懂哥知道要等多久？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8365519387, createdName=王东海, createdTime=Sun Apr 03 11:42:42 CST 2022, time=2022-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200894, encodeId=d3731200894cf, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/KdrBjyWEfR7CoFzpVJic1hDXto8icfp5icEyjqFQvKQwhcHibic1Faxqia9fude7cicf3eXs9A4PHHyax8icKXib0pia7V9A/132, createdBy=1d005326403, createdName=陆昵称, createdTime=Wed Mar 09 14:55:16 CST 2022, time=2022-03-09, status=1, ipAttribution=)]

2022-03-09 陆昵称

审稿速度:1.0 | 投稿命中率:5.0
经验分享：作为临床和基础结合的老牌杂志，要求非常高，既要与临床疾病有很好的相关性，也要有细致的动物模型和分子机制。在临床/基础领域，以前仅次于Nature Medicine，不过现在NM转型发clinical trial了。相对于其他杂志，国人在JCI上发文极少，需要努力。

71 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务